
Hims & Hers Slumps 10% After Q1 Miss, Regulators Scrutinize Telehealth Giant
Hims & Hers Health posted first-quarter revenue of $608 million and a loss of $0.40 per share, missing expectations of $616.8 million and $0.03, which sent the stock down as much as 10% after hours. The company raised its full-year revenue guidance to about $2.8–3.0 billion from a prior range, with Q2 revenue seen around $2.7 billion by analysts. The results come amid regulatory scrutiny after a Wegovy-like rollout was pulled following a Novo Nordisk lawsuit, and ongoing GLP-1 drug partnerships with Novo Nordisk. Analysts maintain a Moderate Buy rating with a $28.02 price target, implying modest downside from current levels.












